|Bid||30.00 x 2200|
|Ask||61.37 x 1100|
|Day's range||38.25 - 40.33|
|52-week range||27.99 - 43.75|
|Beta (5Y monthly)||1.34|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study. Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD. Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy.